India plans to increase its pharmaceutical exports tenfold, targeting $350 billion by 2047. The country will focus on specialty generics, biosimilars, and innovative pharmaceutical products to achieve this ambitious goal. Currently, India ranks 11th in pharmaceutical export value but aims to be among the top five global exporters by 2047.
To achieve this goal, India will shift from a volume-based approach to a value-driven strategy, particularly in Active Pharmaceutical Ingredients (APIs) and biosimilars. Investments in research and development will foster innovation and drive growth. Collaboration between the government and private sectors will also play a crucial role in supporting these initiatives.
Policy measures will strengthen the pharmaceutical ecosystem, enhance manufacturing capabilities, and ensure compliance with international standards. By focusing on high-quality, cost-effective pharmaceutical solutions, India seeks to become a global leader in the industry.
Achieving this vision requires strategic planning, sustained efforts, and continuous innovation. With the right support and a clear roadmap, India’s pharmaceutical industry is set to make significant strides, contributing to the country’s economic growth and global standing.
